Inhibition of system Xc- transporter attenuates autoimmune inflammatory demyelination

Journal of Immunology

Volumn 195, Issue 2, 2015, Pages 450-463

  Evonuk, Kirsten S ^a,b   Baker, Brandi J ^a,b   Doyle, Ryan E ^a,b   Moseley, Carson E ^c   Sestero, Christine M ^d,e   Johnston, Bryce P ^a,b   De Sarno, Patrizia ^f   Tang, Andrew ^b   Gembitsky, Igor ^b   Hewett, Sandra J ^g   Weaver, Casey T ^c   Raman, Chander ^d   DeSilva, Tara M ^a,b,h  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF MONTEVALLO   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g SYRACUSE UNIVERSITY   (United States)

^h University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE TRANSPORTER; GLUTAMIC ACID; MYELIN; SYSTEM XC TRANSPORTER; UNCLASSIFIED DRUG; 4-CARBOXYPHENYLGLYCINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID TRANSPORTER; BENZOIC ACID DERIVATIVE; GLUTAMINE; GLYCINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; SALAZOSULFAPYRIDINE; SLC7A11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; COCULTURE; CONTROLLED STUDY; DEMYELINATING DISEASE; EXCITOTOXICITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; LYMPHOCYTIC INFILTRATION; MALE; MICROGLIA; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LONG EVANS RAT; LYMPHOCYTE ACTIVATION; METABOLISM; MYELIN SHEATH; NEWBORN; PATHOLOGY; PRIMARY CELL CULTURE;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; ANIMALS, NEWBORN; BENZOATES; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXCITATORY AMINO ACID ANTAGONISTS; GENE EXPRESSION; GLUTAMINE; GLYCINE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MYELIN SHEATH; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OLIGODENDROGLIA; PRIMARY CELL CULTURE; RATS; RATS, LONG-EVANS; SULFASALAZINE; TH1 CELLS;

EID: 84936805520     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401108     Document Type: Article

References (72)

1. Pitt, D., E. Gonzales, A. H. Cross, and M. P. Goldberg. 2010. Dysmyelinated axons in shiverer mice are highly vulnerable to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity. Brain Res. 1309: 146-154.
2. Lee, Y., B. M. Morrison, Y. Li, S. Lengacher, M. H. Farah, P. N. Hoffman, Y. Liu, A. Tsingalia, L. Jin, P. W. Zhang, et al. 2012. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487: 443-448.
3. Follett, P. L., P. A. Rosenberg, J. J. Volpe, and F. E. Jensen. 2000. NBQX attenuates excitotoxic injury in developing white matter. J. Neurosci. 20: 9235-9241.
4. Manning, S. M., D. M. Talos, C. Zhou, D. B. Selip, H. K. Park, C. J. Park, J. J. Volpe, and F. E. Jensen. 2008. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J. Neurosci. 28: 6670-6678.
5. DeSilva, T. M., and P. A. Rosenberg. 2012. Glutamate receptors, transporters, and periventricular leukomalacia. In The Biology of Oligodendrocytes. P. Armati and E. Mathey, eds. Cambridge University Press, New York, p. 186-201.
6. Wrathall, J. R., Y. D. Teng, and R. Marriott. 1997. Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma. Exp. Neurol. 145: 565-573.
7. Tekkök, S. B., and M. P. Goldberg. 2001. Ampa/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J. Neurosci. 21: 4237-4248.
8. Matute, C., M. V. Sánchez-Gómez, L. Martínez-Millán, and R. Miledi. 1997. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc. Natl. Acad. Sci. USA 94: 8830-8835.
9. McDonald, J. W., S. P. Althomsons, K. L. Hyrc, D. W. Choi, and M. P. Goldberg. 1998. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat. Med. 4: 291-297.
10. Pitt, D., P. Werner, and C. S. Raine. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6: 67-70.
11. Smith, T., A. Groom, B. Zhu, and L. Turski. 2000. Autoimmune encephalo-myelitis ameliorated by AMPA antagonists. Nat. Med. 6: 62-66.
12. Groom, A. J., T. Smith, and L. Turski. 2003. Multiple sclerosis and glutamate. Ann. N.Y. Acad. Sci. 993: 229-275; discussion 287-288.
13. Bannerman, P., M. Horiuchi, D. Feldman, A. Hahn, A. Itoh, J. See, Z. P. Jia, T. Itoh, and D. Pleasure. 2007. GluR2-free alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors intensify demyelination in experimental autoimmune encephalomyelitis. J. Neurochem. 102: 1064-1070.
14. Stover, J. F., U. E. Pleines, M. C. Morganti-Kossmann, T. Kossmann, K. Lowitzsch, and O. S. Kempski. 1997. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest. 27: 1038-1043.
15. Srinivasan, R., N. Sailasuta, R. Hurd, S. Nelson, and D. Pelletier. 2005. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectros-copy at 3 T. Brain 128: 1016-1025.
16. Bridges, R. J., N. R. Natale, and S. A. Patel. 2012. System xc? cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br. J. Pharmacol. 165: 20-34.
17. Lewerenz, J., S. J. Hewett, Y. Huang, M. Lambros, P. W. Gout, P. W. Kalivas, A. Massie, I. Smolders, A. Methner, M. Pergande, et al. 2013. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18: 522-555.
18. Nabeyama, A., A. Kurita, K. Asano, Y. Miyake, T. Yasuda, I. Miura, G. Nishitai, S. Arakawa, S. Shimizu, S. Wakana, et al. 2010. xCT deficiency accelerates chemically induced tumorigenesis. Proc. Natl. Acad. Sci. USA 107: 6436-6441.
19. Chung, W. J., and H. Sontheimer. 2009. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J. Neurochem. 110: 182-193.
20. Domercq, M., M. V. Sánchez-Gómez, C. Sherwin, E. Etxebarria, R. Fern, and C. Matute. 2007. System xc-and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J. Immunol. 178: 6549-6556.
21. 2 on hypoglycaemic neuronal cell death. ASN Neuro 4: e00074. Available at: http://asn.sagepub.com/content/4/1/AN20110030.full.
22. DeSilva, T. M., A. Y. Kabakov, P. E. Goldhoff, J. J. Volpe, and P. A. Rosenberg. 2009. Regulation of glutamate transport in developing rat oligodendrocytes. J. Neurosci. 29: 7898-7908.
23. Axtell, R. C., B. A. de Jong, K. Boniface, L. F. van der Voort, R. Bhat, P. De Sarno, R. Naves, M. Han, F. Zhong, J. G. Castellanos, et al. 2010. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16: 406-412.
24. Sestero, C. M., D. J. McGuire, P. De Sarno, E. C. Brantley, G. Soldevila, R. C. Axtell, and C. Raman. 2012. CD5-dependent CK2 activation pathway regulates threshold for T cell anergy. J. Immunol. 189: 2918-2930.
25. Axtell, R. C., M. S. Webb, S. R. Barnum, and C. Raman. 2004. Cutting edge: critical role for CD5 in experimental autoimmune encephalomyelitis: inhibition of engagement reverses disease in mice. J. Immunol. 173: 2928-2932.
26. De Sarno, P., R. C. Axtell, C. Raman, K. A. Roth, D. R. Alessi, and R. S. Jope. 2008. Lithium prevents and ameliorates experimental autoimmune encephalo-myelitis. J. Immunol. 181: 338-345.
27. Göbel, K., S. Bittner, T. Ruck, T. Budde, E. Wischmeyer, F. Döring, H. Wiendl, and S. G. Meuth. 2011. Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. J. Immunol. Methods 367: 27-32.
28. Muller, D. M., M. P. Pender, and J. M. Greer. 2000. A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol. 100: 174-182.
29. Albayram, O., J. Alferink, J. Pitsch, A. Piyanova, K. Neitzert, K. Poppensieker, D. Mauer, K. Michel, A. Legler, A. Becker, et al. 2011. Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc. Natl. Acad. Sci. USA 108: 11256-11261.
30. Pampliega, O., M. Domercq, F. N. Soria, P. Villoslada, A. Rodŕiguez-Antigüedad, and C. Matute. 2011. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J. Neuroinflammation 8: 63.
31. Wahl, C., S. Liptay, G. Adler, and R. M. Schmid. 1998. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101: 1163-1174.
32. Hepworth, M. R., L. A. Monticelli, T. C. Fung, C. G. Ziegler, S. Grunberg, R. Sinha, A. R. Mantegazza, H. L. Ma, A. Crawford, J. M. Angelosanto, et al. 2013. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498: 113-117.
33. Chintala, S., W. Li, M. L. Lamoreux, S. Ito, K. Wakamatsu, E. V. Sviderskaya, D. C. Bennett, Y. M. Park, W. A. Gahl, M. Huizing, et al. 2005. Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proc. Natl. Acad. Sci. USA 102: 10964-10969.
34. Rasmussen, S., Y. Wang, P. Kivisäkk, R. T. Bronson, M. Meyer, J. Imitola, and S. J. Khoury. 2007. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 130: 2816-2829.
35. Jäger, A., V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo. 2009. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomy-elitis with different pathological phenotypes. J. Immunol. 183: 7169-7177.
36. Kuchroo, V. K., and A. Awasthi. 2012. Emerging new roles of Th17 cells. Eur. J. Immunol. 42: 2211-2214.
37. Li, J., O. Baud, T. Vartanian, J. J. Volpe, and P. A. Rosenberg. 2005. Perox-ynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. USA 102: 9936-9941.
38. Axtell, R. C., C. Raman, and L. Steinman. 2013. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin. Rev. Allergy Immunol. 44: 114-120.
39. Sequeira, S. M., A. F. Ambrosio, J. O. Malva, A. P. Carvalho, and C. M. Carvalho. 1997. Modulation of glutamate release from rat hippocampal synaptosomes by nitric oxide. Nitric Oxide 1: 315-329.
40. Bal-Price, A., and G. C. Brown. 2001. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21: 6480-6491.
41. Brown, G. C. 2010. Nitric oxide and neuronal death. Nitric Oxide 23: 153-165.
42. Fogal, B., J. Li, D. Lobner, L. D. McCullough, and S. J. Hewett. 2007. System x(c)-activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J. Neurosci. 27: 10094-10105.
43. Jackman, N. A., T. F. Uliasz, J. A. Hewett, and S. J. Hewett. 2010. Regulation of system x(c)(-)activity and expression in astrocytes by interleukin-1b: implications for hypoxic neuronal injury. Glia 58: 1806-1815.
44. Bannai, S., and E. Kitamura. 1980. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. J. Biol. Chem. 255: 2372-2376.
45. Chung, W. J., S. A. Lyons, G. M. Nelson, H. Hamza, C. L. Gladson, G. Y. Gillespie, and H. Sontheimer. 2005. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 25: 7101-7110.
46. Siffrin, V., H. Radbruch, R. Glumm, R. Niesner, M. Paterka, J. Herz, T. Leuenberger, S. M. Lehmann, S. Luenstedt, J. L. Rinnenthal, et al. 2010. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33: 424-436.
47. Lee, S. C., D. W. Dickson, W. Liu, and C. F. Brosnan. 1993. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J. Neuroimmunol. 46: 19-24.
48. Chao, C. C., S. Hu, W. S. Sheng, D. Bu, M. I. Bukrinsky, and P. K. Peterson. 1996. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16: 276-284.
49. Hewett, J. A., S. J. Hewett, S. Winkler, and S. E. Pfeiffer. 1999. Inducible nitric oxide synthase expression in cultures enriched for mature oligodendrocytes is due to microglia. J. Neurosci. Res. 56: 189-198.
50. Merrill, J. E., L. J. Ignarro, M. P. Sherman, J. Melinek, and T. E. Lane. 1993. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151: 2132-2141.
51. Buntinx, M., E. Gielen, P. Van Hummelen, J. Raus, M. Ameloot, P. Steels, and P. Stinissen. 2004. Cytokine-induced cell death in human oligodendroglial cell lines. II: Alterations in gene expression induced by interferon-gamma and tumor necrosis factor-alpha. J. Neurosci. Res. 76: 846-861.
52. Buntinx, M., M. Moreels, F. Vandenabeele, I. Lambrichts, J. Raus, P. Steels, P. Stinissen, and M. Ameloot. 2004. Cytokine-induced cell death in human ol-igodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J. Neurosci. Res. 76: 834-845.
53. Hewett, S. J., J. A. Corbett, M. L. McDaniel, and D. W. Choi. 1993. Interferon-gamma and interleukin-1 beta induce nitric oxide formation from primary mouse astrocytes. Neurosci. Lett. 164: 229-232.
54. Vartanian, T., Y. Li, M. Zhao, and K. Stefansson. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1: 732-743.
55. Torres, C., I. Aránguez, and N. Rubio. 1995. Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens. Immunology 86: 250-255.
56. Brenner, T., S. Brocke, F. Szafer, R. A. Sobel, J. F. Parkinson, D. H. Perez, and L. Steinman. 1997. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J. Immunol. 158: 2940-2946.
57. Brown, G. C., and A. Bal-Price. 2003. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27: 325-355.
58. Mander, P., V. Borutaite, S. Moncada, and G. C. Brown. 2005. Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. J. Neurosci. Res. 79: 208-215.
59. Rousset, C. I., J. Kassem, P. Olivier, S. Chalon, P. Gressens, and E. Saliba. 2008. Antenatal bacterial endotoxin sensitizes the immature rat brain to postnatal excitotoxic injury. J. Neuropathol. Exp. Neurol. 67: 994-1000.
60. Tzingounis, A. V., and J. I. Wadiche. 2007. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat. Rev. Neurosci. 8: 935-947.
61. Tanaka, K., K. Watase, T. Manabe, K. Yamada, M. Watanabe, K. Takahashi, H. Iwama, T. Nishikawa, N. Ichihara, T. Kikuchi, et al. 1997. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
62. Sattler, R., and J. D. Rothstein. 2006. Regulation and dysregulation of glutamate transporters. Handbook Exp. Pharmacol. 175: 277-303.
63. Ye, Z. C., and H. Sontheimer. 1998. Glial glutamate transport as target for nitric oxide: consequences for neurotoxicity. Prog. Brain Res. 118: 241-251.
64. Ye, Z. C., and H. Sontheimer. 1996. Cytokine modulation of glial glutamate uptake: A possible involvement of nitric oxide. Neuroreport 7: 2181-2185.
65. Ye, Z. C., and H. Sontheimer. 1999. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 59: 4383-4391.
66. Savaskan, N. E., A. Heckel, E. Hahnen, T. Engelhorn, A. Doerfler, O. Ganslandt, C. Nimsky, M. Buchfelder, and I. Y. Eyüpoglu. 2008. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med. 14: 629-632.
67. Gmünder, H., H. P. Eck, B. Benninghoff, S. Roth, and W. Dröge. 1990. Mac-rophages regulate intracellular glutathione levels of lymphocytes: evidence for an immunoregulatory role of cysteine. Cell. Immunol. 129: 32-46.
68. Yan, Z., S. K. Garg, J. Kipnis, and R. Banerjee. 2009. Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 5: 721-723.
69. Brüstle, A., D. Brenner, C. B. Knobbe, P. A. Lang, C. Virtanen, B. M. Hershenfield, C. Reardon, S. M. Lacher, J. Ruland, P. S. Ohashi, and T. W. Mak. 2012. The NF-kB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J. Clin. Invest. 122: 4698-4709.
70. Prosiegel, M., I. Neu, S. Vogl, G. Hoffmann, A. Wildfeuer, and G. Ruhenstroth-Bauer. 1990. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine. Acta Neurol. Scand. 81: 237-238.
71. Prosiegel, M., I. Neu, G. Ruhenstroth-Bauer, G. Hoffmann, S. Vogl, L. Mehlber, and A. Wildfeuer. 1989. Suppression of experimental autoimmune encephalitis by sulfasalazine. N. Engl. J. Med. 321: 545-546.
72. Noseworthy, J. H., P. O'Brien, B. J. Erickson, D. Lee, D. Sneve, G. C. Ebers, G. P. Rice, A. Auty, W. J. Hader, A. Kirk, et al. 1998. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51: 1342-1352.